Discovery of New Anti-MRSA Agents Based on Phenoxyethanol and Its Mechanism

Area of Science:

• Medicinal Chemistry
• Microbiology
• Drug Discovery

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) presents a significant global health challenge.
• Developing novel anti-MRSA agents with new mechanisms of action is crucial.

Purpose of the Study:

• To design and synthesize novel aryloxyethyl propiolates and their homologues as potential anti-MRSA agents.
• To evaluate the efficacy and mechanism of action of these compounds against MRSA.

Main Methods:

• Synthesis of aryloxyethyl propiolates based on phenoxyethanol.
• Determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC).
• Assessment of effects on cell wall/membrane integrity, biofilm formation, DNA binding, and protein expression via proteomic and metabolomic analyses.

Main Results:

• Compound II-39 demonstrated potent anti-MRSA activity (MIC: 0.78 μg/mL, MBC: 3.13 μg/mL), outperforming vancomycin.
• II-39 disrupted MRSA cell walls and membranes, inhibited biofilm formation, and bound to MRSA DNA.
• Proteomic and metabolomic studies indicated II-39 affects multiple intracellular pathways, including staphyloxanthin biosynthesis by inhibiting CrtPQMN proteins.

Conclusions:

• Aryloxyethyl propiolates, exemplified by II-39, are promising multi-targeted agents against MRSA.
• Compound II-39's ability to inhibit virulence factor biosynthesis offers a novel therapeutic strategy.